Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer - 01/02/22
Doi : 10.1016/S1470-2045(21)00715-4
Hagai Ligumsky a, f 
, Herut Dor f, Tal Etan a, f, Inbal Golomb a, f, Alla Nikolaevski-Berlin a, Inbal Greenberg f, Tamar Halperin b, Yoel Angel c, f, Oryan Henig d, f, Avishay Spitzer a, f, g, Marina Slobodkin e, f, Ido Wolf a, f
in collaboration with the
, Herut Dor f, Tal Etan a, f, Inbal Golomb a, f, Alla Nikolaevski-Berlin a, Inbal Greenberg f, Tamar Halperin b, Yoel Angel c, f, Oryan Henig d, f, Avishay Spitzer a, f, g, Marina Slobodkin e, f, Ido Wolf a, fin collaboration with the
COVI3 study investigators
a Oncology Division, Tel Aviv Sourasky Medical Center 6423906, Tel Aviv, Israel
b Human Immunodeficiency Virus Laboratory, Tel Aviv Sourasky Medical Center 6423906, Tel Aviv, Israel
c Department of Anasthesia, Pain and Intensive Care, Tel Aviv Sourasky Medical Center 6423906, Tel Aviv, Israel
d Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center 6423906, Tel Aviv, Israel
e Department of Internal Medicine “D”, Tel Aviv Sourasky Medical Center 6423906, Tel Aviv, Israel
f Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
g Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
El texto completo de este artículo está disponible en PDF.
© 2022
Elsevier Ltd. Reservados todos los derechos.
Vol 23 - N° 2
P. 193-195 - février 2022 Regresar al número
Artículo precedente
- Overcoming immunotherapy resistance in NSCLC
- Michael MacManus, Fiona Hegi-Johnson
- Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
- Georg Pfeiler, Angela DeMichele, Amylou C Dueck, Christian Fesl, Michael Gnant, Erica L Mayer
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?